Table 3 Univariate analyses of the prognostic factors associated with reactivation/worsening after the first course of vinblastine
Characteristic | N = 35 | HR (95% CI) | p-value |
|---|---|---|---|
Age at vinblastine, years | 33 [28–42] | 1.03 (0.99; 1.08) | 0.13 |
Male sex, n (%) | 23 (66%) | 0.67 (0.26; 1.75) | 0.41 |
Smoking status | |||
Non-smoker | 18 (53%) | 1.00 | |
Ex-smoker | 9 (27%) | 1.15 (0.26; 4.95) | 0.86 |
Smoker | 7 (20%) | 0.91 (0.24; 3.50) | 0.89 |
LCH localizations, n (%) | |||
Bone | 27 (77%) | 0.56 (0.21; 1.48) | 0.27 |
Lung | 17 (49%) | 0.56 (0.21; 1.48) | 0.24 |
Diabetes insipidus | 14 (40%) | 0.60 (0.22; 1.64) | 0.31 |
Anterior hypophysis dysfunction | 14 (40%) | 0.51 (0.15; 1.79) | 0.29 |
Skin | 9 (26%) | 1.95 (0.74; 5.14) | 0.18 |
Peripheral lymph nodes | 10 (29%) | 0.67 (0.15; 2.95) | 0.59 |
Classification of LCH | |||
MS | 28 (80%) | 1.00 | |
SS | 1.46 (0.41; 5.23) | 0.56 | |
First vinblastine dosea | 1.00 (0.96; 1.05) | 0.86 | |
Duration of first course, months | 0.97 (0.89; 1.05) | 0.41 | |